TMEM170 Inhibitors

Wiskostatin, a GLUT1 inhibitor, controls glucose entry into the cell, which is critical for glycosylation, a post-translational modification that could be essential for TMEM170's function or stability. Genistein, by inhibiting tyrosine kinases, may alter signaling cascades that TMEM170 is part of or regulated by. Bafilomycin A1 and Dynasore interfere with vesicle acidification and GTPase activity, respectively, impacting the endocytic pathway and potentially affecting TMEM170's trafficking or membrane localization. Compounds like Decynium-22 and Endothall alter membrane potential and ion gradients, which can indirectly influence the conformation or activity of TMEM170 embedded within the membrane.

ML-9 and Gö6976, by targeting myosin light-chain kinase and protein kinase C, respectively, can modulate the cytoskeleton and intracellular signaling pathways, possibly affecting TMEM170's positioning or interactions within the cell. PD150606 prevents the proteolytic activity of calpain, which may protect TMEM170 from cleavage and degradation. Monensin, as a disruptor of Golgi function, could impede the correct glycosylation and sorting of TMEM170, crucial for its function. U73122, by inhibiting phospholipase C, affects the production of second messengers, which may be involved in the regulation of TMEM170. Lastly, Triacsin C's inhibition of acyl-CoA synthetase can alter lipid profiles within cellular membranes.